Orthofix Announces New Term Loan

New Financing Replaces Existing Term Loan and Seeks to Further Optimize the Company’s Capital Structure to Support Long-Term, Profitable Growth

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the entry into a new credit agreement providing the Company with up to $275 million in a senior-secured term loan with a 48-month interest only period. The term loan is agented by Oxford Finance LLC (“Oxford”) and provides non-dilutive capital and financial flexibility to support Orthofix’s continued focus on profitable growth. The proceeds from the initial funding of the term loan will be used to retire the Company’s existing credit facility and pay related fees and expenses. The remaining capacity will bolster the Company’s access to capital.

HarmonyCares Secures $200M to Expand Access to In-Home Primary Care

HarmonyCares, a leading provider of value-based in-home longitudinal care, today announced that it has raised $200M of capital to bring its integrated, physician-led in-home care model to more vulnerable patients nationwide. The funding round was led by General Catalyst, McKesson Ventures, and a large national payor which were joined by K2 HealthVentures and existing investors, Rubicon Founders, Valtruis, HLM Capital, and Oak HC/FT to expand HarmonyCares services to additional geographies and develop new technology to drive clinical outcomes and patient satisfaction at scale.

Life Science Cares Boston launches Health Equity Portfolio Co-Investment Program as part of Anti-Poverty Strategy for Greater Boston

[Cambridge, MA June 3, 2024] — Life Science Cares Boston (LSC Boston), an anti-poverty nonprofit organization rooted in the life sciences, is proud to announce the launch of a new grantmaking program aimed at addressing health inequities among low-income families and communities in the Greater Boston area.

Since 2016, LSC Boston has leveraged the talent, passion, and community investments of the life science industry to fight poverty and provide a platform for the city’s leading industry to make a difference in the community. Through leveraging partnerships with life science companies and executives, LSC Boston has granted nearly $10 Million to 85 nonprofits providing access to Basic Needs, Education, and Economic Opportunity.

LSC Boston is now expanding their commitment to disrupt the cycle of poverty by launching a new Health Equity program that invests in nonprofits improving health and wellness across three areas: Safe Homes & Vibrant Communities; Access to Equitable, Dignified Care; and Advocacy and Civic Wellness. Through this initiative, LSC Boston will provide crucial support to organizations delivering innovative, community-based solutions that improve health outcomes and foster vibrant, resilient communities.

K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries, has partnered with LSC Boston as the seed funder for this initiative.

“We are proud to join Life Science Cares Boston in their mission to create a healthier, more equitable Boston. K2 HealthVentures was built on the idea of ‘profit with a purpose’ and since our founding, giving back to our community and supporting underserved areas in healthcare has been core to our work,” said Parag Shah, Founding Managing Director & CEO of K2 HealthVentures. “This investment exemplifies the power of collaboration between the private sector and nonprofit organizations to address complex societal challenges. We are grateful for the opportunity to partner with Life Science Cares Boston to support our shared passion for improving outcomes for those most in need.”

In recognition of their innovative vision and commitment to disrupting the cycle of poverty in Greater Boston, K2 HealthVentures was awarded the 2024 Luke Timmerman Impact Award by Life Science Cares Boston.

“This work will be a new focus of our work at Life Science Cares Boston,” said Yvonne Spicer, EdD, Executive Director of LSC Boston. “Through this pilot program, we hope to show our ability to make a significant collective impact on health outcomes and promote social justice in our community.”
LSC Boston invites potential investors and philanthropic partners to join in this critical effort to address health inequities and create a healthier, more equitable future for all.

Nonprofit organizations interested in applying for grants can expect a transparent and structured process, with grants ranging from $15,000 to $75,000 per year, to provide unrestricted funding, awarded in two-year increments.

“The reality is that income and health are inextricably linked,” said Kelly Brawn, PhD, Head of Programs and Community Engagement at LSC Boston. “I’m incredibly proud of the impact we have and continue to make, but it is clear that we can—and therefore must—do more to disrupt the pernicious cycle of poverty. Investing in creative solutions that improve the health of our neighbors will allow us to do just that.”

From ensuring high-quality maternal health to disrupting systems that perpetuate the cycle of poverty to providing equal access to green space, this new program allows us to reach further into our community and support more of our neighbors in need.

For more information on how to apply or become a co-investor, please visit www.lifesciencecares.org/health-equity

Life Science Cares (LSC) activates the financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in our communities. LSC was founded to move the needle on issues of poverty, while helping companies build connections with the community and internally between employees.

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Merck Completes Acquisition of Harpoon Therapeutics, Inc.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market.

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share. All of the common shares are being sold by MindMed. Gross proceeds to MindMed from the underwritten offering and concurrent private placement, before deducting underwriting commissions, placement agent fees and other offering-related expenses, are expected to be approximately $175 million.

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD). The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

CAMBRIDGE, Mass. – VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced agreements whereby Brii Biosciences (“Brii Bio”), subject to certain activities, is expected to: (i) acquire the intellectual property for VBI-2601, VBI’s HBV immunotherapeutic development program, and eliminate payment obligations from the July 2023 agreements between VBI and Brii Bio, (ii) acquire manufacturing capabilities and certain related assets at VBI’s Rehovot, Israel manufacturing facility, and (iii) enter into an exclusive license to develop and commercialize VBI-1901, VBI’s glioblastoma (GBM) immunotherapeutic candidate, in the Asia Pacific region (APAC), excluding Japan. Additionally, subject to certain approvals, VBI and Brii Bio will work together to transfer the manufacturing technologies of VBI-2601 to a site designated by Brii Bio. VBI received $2.5 million of consideration upon signing of definitive documents and is expected to receive up to an additional $30.5 million of consideration, subject to achievement of certain activities, with a target completion date of June 30, 2024.

Alto Neuroscience Announces Pricing of Upsized Initial Public Offering

NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 648,750 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Corbus. The offering is expected to close on or about February 2, 2024, subject to customary closing conditions.

Corbus Pharmaceuticals Announces Pricing of Public Offering

NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 648,750 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Corbus. The offering is expected to close on or about February 2, 2024, subject to customary closing conditions.

Inari Accelerates Proven SEEDesign™ Platform for Nature-Positive Agriculture with $103 Million Fundraise

CAMBRIDGE, Mass., January 30, 2024 — Inari today announced the completion of a $103 million fundraise, bringing its cumulative equity raised to more than $575 million. The successful investment round signals confidence in Inari’s ability to develop and commercialize higher-yielding seeds that require fewer resources, using AI-powered predictive design and multiplex gene editing.  

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study…

NORWOOD, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Company’s development partner CSPC Pharmaceutical Group at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The Phase 1 dose escalation study is being conducted in China and is enrolling participants with metastatic urothelial cancer (mUC) as well as participants with other solid tumors prospectively confirmed to have nectin-4 positive tumors. The study opened for enrollment in January 2023 and data through December 2023 from the first eighteen participants reflective of the first six dose cohorts (0.2-3.6mg/kg) will be shared.

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), today announced that it has entered into a senior secured loan and security agreement (the “Loan Agreement”) with K2 HealthVentures, a healthcare-focused specialty finance company.

Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023

NEW YORK – October 23, 2023 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain.

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types in a poster at the European Society of Medical Oncology Congress (ESMO) 2023. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells.

Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient in the Phase 2 COLLECTiVE202 clinical study of VE202 was dosed. Vedanta also announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE202, for the treatment of ulcerative colitis (UC). Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.

CareSource and Spark Pediatrics Partner to Serve Florida Medicaid Enrollees

(MIAMI, FL – Sept. 27, 2023) – CareSource, a nationally recognized managed care organization, and Spark Pediatrics, the leading provider of prescribed pediatric extended centers (PPEC or Medical Daycare) in both Florida and nationally, announced today the launch of ImagineCare -- a partnership to serve Florida Medicaid enrollees as a Provider Service Network (PSN). ImagineCare is an innovative managed care organization focused on deploying a provider-driven, community-centric, value-based care model for enrollees with medical complexities.

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

Invaio Achieves First Registration for Citrus Greening Solution Featuring Trecise™ Technology